XYLT2 Antibody

Product Discontinued

XYLT2 Antibody Summary

• Immunogen: This antibody was developed against Recombinant Protein corresponding to amino acids:GTPALKAYWENTYDAADGPSGLSDVMLTAYTAFARLSLHHAATAAPPMGTPLCRFEPRGLPSSVHLYFYDDHFQGYLVTQAVQPSAQGPAETLEMWLMPQGS
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: XYLT2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1 - 4 ug/ml
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:20-1:50
• Application Notes: For IHC-Paraffin, HIER pH 6 retrieval is recommended. Immunocytochemistry/Immunofluorescence Fixation Permeabilization: Use PFA/Triton X-100.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2) and 40% Glycerol
• Preservative: 0.02% Sodium Azide
• Purity: Immunogen affinity purified

Alternate Names for XYLT2 Antibody

• EC 2.4.2.26
• Peptide O-xylosyltransferase 1
• PXYLT2
• XT2UDP-D-xylose:proteoglycan core protein beta-D-xylosyltransferase
• xylosyltransferase 2
• xylosyltransferase IIXT-IIprotein xylosyltransferase 2
• xylT-II

Background

The protein encoded by the XYLT2 gene is an isoform of xylosyltransferase, which belongs to a family ofglycosyltransferases. This enzyme transfers xylose from UDP-xylose to specific serine residues of the core protein andinitiates the biosynthesis of glycosaminoglycan chains in proteoglycans including chondroitin sulfate, heparansulfate, heparin and dermatan sulfate. The enzyme activity, which is increased in scleroderma patients, is adiagnostic marker for the determination of sclerotic activity in systemic sclerosis. (provided by RefSeq)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for XYLT2 Antibody (NBP1-87181)(1)

Publication using NBP1-87181

• Dziedzic D, Wegrzyn G, Jakobkiewicz-Banecka J. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet. 2009-08-19 [PMID: 19690584]

Bioinformatics

• Gene Symbol: XYLT2